Gefitinib plus Fuzheng Kang ’ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: A randomized controlled trial

ConclusionPatients with advanced non-small cell lung cancer selected by EGFR mutations have longer PFS, MST and with less toxicity if they are treated with gefifitinib plus FZKA than gefifitinib alone.
Source: Chinese Journal of Integrative Medicine - Category: Internal Medicine Source Type: research